DGAP-News

BB BIOTECH AG: Annual report 2016

DGAP-News: BB BIOTECH AG / Key word(s): Final Results BB BIOTECH AG: Annual report 2016 (news with additional features) 17.02.2017 / 07:00 The issuer is solely responsible for the content of this announcement. Media release as of February 17, 2017

Annual report of BB Biotech AG as of December 31, 2016

 

BB Biotech AG publishes its 2016 annual report

BB Biotech AG published its annual report for fiscal 2016 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the biotechnology sector, BB Biotech's positioning, the therapeutic areas covered by its portfolio and the companies it is invested in.

As disclosed in the report, BB Biotech ended the year with a slightly positive total return of 0.3% in CHF and 1.9% in EUR despite the considerable difficulties the past year posed for biotech investors. Its Net Asset Value (NAV) declined by 19.1% in CHF, 17.6% in EUR and 20.6% in USD, which was somewhat better than the benchmark Nasdaq Biotech Index. The performance of BB Biotech's shares in 2016 largely reflects the dissolution of the discount to NAV. The consolidated and audited accounts show a net loss of CHF 802 mn for fiscal 2016 compared to a net profit of CHF 653 mn in the previous year.

As already announced on January 20, 2017, BB Biotech will propose an ordinary dividend of CHF 2.75 per share at the upcoming Annual General Meeting, which represents a yield of 5% based on the volume-weighted average price of BB Biotech shares in December 2016. This marks a continuation of the dividend policy as introduced in 2013.

BB Biotech's annual report 2016 can be downloaded at www.bbbiotech.com.

 

For further information:

Investor Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. [phone]
Dr. Silvia Schanz, [e-mail]

Maria-Grazia Iten-Alderuccio, [e-mail]

Claude Mikkelsen, [e-mail]